Larvol Delta - Exposureresponse-analysis-of-Camidanlumab-tesirine-in-patients-with-relapsed-or-refractory-classical-Hodgkin-lymphoma-and-nonHodgkin-lymphoma

camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/36333463

Nov 6, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next